Boston Scientific ($BSX) Electrophysiology Growth Guidance Case

Investors can submit applications for the lead plaintiff role.

D. Massachusetts

Court

4:26-cv-40075

Case number

07/23/2025

Class period Start

02/03/2026

Class period End

05/04/2026

Lead Plaintiff motion deadline

$BSX investors filed a claim against Boston Scientific for allegedly overstating the durability of growth in its U.S. electrophysiology (EP) business while downplaying competitive and market pressures.
After the company reported disappointing U.S. EP sales and issued weaker-than-expected 2026 guidance, $BSX fell 17.6% on February 4, 2026, closing at $75.50 per share.
$BSX investors can join this case to be notified about potential recovery.
Case Details:

Between July 23, 2025 and February 3, 2026, Boston Scientific told investors its electrophysiology (EP) business was positioned for strong and sustained growth. Executives emphasized strong adoption of its FARAPULSE technology, expanding market share, and confidence that the company understood and could manage competitive dynamics while repeatedly raising full-year guidance.

However, during this period, investors allege the company’s U.S. EP growth trajectory was already weakening. Boston Scientific allegedly failed to disclose: (1) that growth in its EP segment was becoming unsustainable as the market matured; (2) that new competitors were entering the market and beginning to erode the company’s U.S. EP market share earlier than expected; and (3) that these pressures would reduce EP sales growth and ultimately force the company to lower expectations.

Then, on February 4, 2026, the company reported fourth-quarter 2025 results that included disappointing U.S. EP sales and issued fiscal 2026 growth guidance below market expectations. $BSX fell 17.6%, closing at $75.50. By February 4, shares had dropped to $75.50, representing a total decline of 17.6% over the correction period.

Based on these events, $BSX investors filed a claim against Boston Scientific, alleging the company:
It overstated the durability of growth in its electrophysiology business.
It downplayed the impact of new competitors and slowing market growth on its EP segment.
It misled investors about the company’s true growth outlook and future guidance.
Investors argue Boston Scientific misled the market about the sustainability of its U.S. electrophysiology growth, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

02/04/2026

Filing date

03/05/2026

Lead Plaintiff Deadline

05/04/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.